Microgestin Fe 1.5/30 (NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE)
Microgestin Fe 1.5/30 (NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Microgestin Fe 1.5/30; Generic name: NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE; Manufacturer: Dr. Reddys Laboratories Inc.
| Brand name | Microgestin Fe 1.5/30 |
|---|---|
| Generic name | NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE |
| Manufacturer | Dr. Reddys Laboratories Inc |
| Used for | INDICATIONS AND USAGE Microgestin Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. table1 |
| Dosage | DOSAGE AND ADMINISTRATION The compact tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the compact tablet dispenser above the first row of tablets. Note: Each compact tablet dispenser has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label stickers have been provide |
| Warnings | WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practi |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17b4ee33-3ec1-440d-9446-f20c51629c2d |